1. Introduction {#sec1}
===============

Obesity has developed into an epidemic. Approximately 1.7 billion people are overweight, and 312 million are obese \[[@B1], [@B2]\]. In Germany in 2009, 60.1% of male and 42.9% of female population were overweight \[[@B3]\]. Morbid obesity is associated with increased health costs and an increased mortality risk \[[@B4], [@B5]\].

As a result of new technologies with lower risks and better long-term results, bariatric and metabolic surgeries have grown in popularity in recent years. The number of operations performed is rapidly increasing. However, bariatric surgery is associated with numerous peri- and postoperative complications. Venous thromboembolism is the most common postoperative complication. Obesity needs to be considered as one of the most serious factors predisposing patients to the development of thrombosis and pulmonary embolism. In addition, the risk for thromboembolism in metabolic surgery is high, and its detection is complicated. The guidelines of the German Society of Surgery suggest that there is a high risk of deep venous thrombosis (VTE) and pulmonary embolism (PE) for patients who undergo bariatric surgery. An even higher risk for the development of a thrombosis is reported by the German AWMFguidelines \[[@B6]\]. International guidelines refer to an independent risk for the occurrence of fulminate pulmonary embolism in obese patients. Current "ASBMS" guidelines recommend local compressions and anticoagulation \[[@B7]\].

Actually, the optimal approach for prophylaxis of VTE in bariatric operations as well as obese patients is unknown. The risk of VTE and its complications has to be balanced with the increased bleeding risk. In the literature, there have been no randomized studies examining the correlation between VTE, pulmonary embolism (PE), and the various options for VTE prophylaxis in bariatric surgery \[[@B8]\]. Recent published meta-analysis show the relatively low risk with standard regimen for antithrombotic prophylaxis, but an increasing bleeding risk, when weight-adjusted dose of heparin were used \[[@B9]\].

The aim of this study evaluating the data of the German Nationwide Survey on Bariatric Surgery was to investigate the specific complications of thrombosis and pulmonary embolism in the perioperative course in Germany and to compare our findings with data from the literature.

2. Patients and Methods {#sec2}
=======================

Data from the Study for quality assurance in bariatric surgery in Germany have been prospectively obtained from January 1, 2005 \[[@B10]\] using an online data registry. For current evaluation, data from 2005 to 2010 were analyzed. Incidence and risk of VTE for the most performed metabolic procedures gastric banding (GB), sleeve gastrectomy (SG), and Roux-en-Y-gastric bypass (RYGBP) have been evaluated. Peri-interventional characteristics and parameters, such as BMI as well as the frequency, type, application mode, and duration of medication in VTE and PE, were determined in connection to the operative procedure. Follow-up data, which are available for 63.8% of patients, were used to elucidate the incidence of VTE and PE after discharge. To appropriately interpret the results, a literature search was initiated.

3. Results {#sec3}
==========

3.1. Operations {#sec3.1}
---------------

Since 2005 the number of primary metabolic operations has been increasing, rapidly.

We reporting on 12,  296 primary bariatric procedures including 668 implantations of gastric balloons (BIB), 2730 GB, 4901 RYGBP, 3042 SG, 120 biliopancreatic diversion (BPD), and 163 duodenal switch (DS) and 211 other procedures.

3.2. Demographic Data {#sec3.2}
---------------------

In total 72.5% female patients and 27.5% male patients were operated between 2005 and 2010. Mean age for all patients was 42.2 years (range 11--79 years) and mean BMI 48.8 kg/m² (range 23.7--115 kg/m²).

Mean age for women (40.9 years, range 11--79 years) was significantly lower than for men (43.6 years, range 14--79 years) (*P* \> 0.001). Mean BMI was for women 48.1 kg/m² (range 23.7--115.0 kg/m²) and 50.1 kg/m² (range 27.4--10.2 kg/m²) for men.

3.3. Comorbidities {#sec3.3}
------------------

For risk analysis the incidence of comorbidities is important. In German Nationwide Survey on Bariatric Surgery the incidence of comorbidities is high. At the different periods from 2005 to 2010 the incidence on comorbidities did not change. 57.3% of patients suffering on hypertension, 17.5% on pulmonary diseases, 9.7% on cardiac comorbidities, 14.9% on gastroesophageal reflux disease, and 43.6% on skeleton disease. Incidence on patients with insulin-dependent diabetes is 10.0% and with noninsulin-dependent diabetes is 19.1% (*P* \< 0.001) ([Table 1](#tab1){ref-type="table"}).

3.4. Operation and Thromboembolic Prophylaxis {#sec3.4}
---------------------------------------------

Prophylaxis of VTE and PE depends on the kind of operation. Through the observation period from 2005 to 2010, a significant reduction of patients undergoing GB procedure and who had previously undergone prophylaxis for thromboembolism with medication was found (*P* \< 0.001), respectively ([Table 2](#tab2){ref-type="table"}). In cases of complex surgical interventions like biliopancreatic diversion (BPD) and duodenal switch (DS), prophylactic medication was given to all patients.

The duration of prophylaxis of thromboembolism correlated significantly with the length of hospital stay, which ranged from 6 to 8 days (*P* \< 0.001) ([Table 3](#tab3){ref-type="table"}).

LMWH was used for prophylaxis in 98.5% of the patients; only in 1.5% of patients were unfractionated heparin used for prophylaxis. No prophylaxis with cava filters is reported to German Nationwide Survey.

In 2005, there was no association between BMI and the frequency of prophylaxis administration for thromboembolism. In contrast, there was a tendency to administer low-molecular-weight heparin twice a day during the following years. Patients who received two administrations showed a higher BMI (once a day, BMI = 48.5 kg/m²; twice a day, BMI = 51.5 kg/m² (*P* \< 0.001). Therefore, patients with two applications for thromboembolism prophylaxis showed a significantly higher BMI through the whole study period ([Table 4](#tab4){ref-type="table"}).

3.5. Risks for VTE and PE {#sec3.5}
-------------------------

VTE risk and risk of fatal PE could not evaluate any significant difference in dependence on operative procedure for the most performed procedures GB, SG, and RYGBP ([Table 5](#tab5){ref-type="table"}).

Overall incidence of VTE was 0.06% (8/11835) and for PE 0.08% (10/11835). Comparing gender-specific risks for VTE we found no significance difference between men and women. Risk for female patients is 0.06% and for male patients 0.09% (*P* = 0.5216). Increasing BMI correlates with a higher incidence on VTE until BMI of 49.9 kg/m². In patients with BMI above 50 kg/m² the VTE incidence dropped down ([Table 6](#tab6){ref-type="table"}). Evaluated risk for VTE at the 90 first postoperative days is for all procedures ≤0.10%.

Incidence of PE for GB, SG, and RYGBP in German Nationwide Survey was ≤0.20% ([Table 5](#tab5){ref-type="table"}). According gender-specific aspects exist no significance difference for developing PE 90 days postoperatively (*P* = 0.5085). Risk factor for female patients was 0.08% (relative risk 0. 8773%) and for male patients 0.12% (relative risk 1.3242%) ([Table 6](#tab6){ref-type="table"}).

4. Discussion {#sec4}
=============

German Nationwide Survey has evaluated the risk of VTE (0.06%) and PE (0.08%) in bariatric surgery Germany between 2005 and 2010. VTE or PE has been reported to the survey, when it was diagnosed by vascular ultrasound, CT scan, or echocardiography.

According to the literature, the risk for the development of a PE after bariatric surgery is between 0.1% and 1.3% \[[@B11], [@B12]\]. The risk for thromboembolic complications in bariatric surgery in patients who did not receive in-hospital chemoprophylaxis is 2.4% \[[@B12], [@B13]\]. In particular, fatal PE (0.3%) needs to be considered as the strongest independent factor for perioperative mortality. DeMaria et al. have reported a mortality of 0.23% due to PE (10/4431 patients) \[[@B14]\]. Data of BOLD-Registry have shown a VTE risk 90 days postoperatively of 0.42% (*n* = 73, 971). 73% of VTE in this study have been developed after patients discharge during the first 30 days \[[@B15]\]. However, no evidence-based data on optimal prophylaxis exist \[[@B9], [@B14]\]. According German AWMF-Guidelines and ACCP-Guidelines visceral surgery and morbid obesity is associated with the highest risk for VTE and PE \[[@B16]\]. Benefit and risk of bleeding has to be considered if weight-adjusted LWMH is used for prophylaxis \[[@B9], [@B14], [@B15]\]. Using LWMH prophylaxis with pneumatic compression is widely used in bariatric surgery. Advantage of pneumatic compression in laparoscopic bariatric surgery is defending of venous stasis in lower extremity.

German Nationwide Survey has a significant reduction of antithrombotic prophylaxis for patients undergoing GB evaluated. This fact can be associated with the fact that GB is implanted during a short hospital stay of one or two days in several hospitals. For these patients we did not evaluate a higher incidence of VTE. As a bias of our study we cannot exclude that clinical symptoms of VTE or PE for these patients were not documented at the registry.

In patients with BMI above 50 kg/m² the incidence of VTE dropped down. In this fact as a bias of the study we cannot exclude that patients with BMI above 50 kg/m² were treated with higher dose of LMWH, mostly. A second limitation is that patients with BMI above 55--60 kg/m² in Germany were first treated with BIB to reduce overall complication rate. Implantation of BIB is most performed without VTE prophylaxis. For laparoscopic interventions, data obtained in a randomized study by Nguyen et al. suggest that hypercoagulability caused a higher incidence of PE \[[@B17]\]. In addition, pneumoperitoneum is a potential risk factor due to the resulting venous stasis of the lower extremity, which is increased by the anti-Trendelenburg position \[[@B18]\]. In German Nationwide Survey, however, this effect could not be detected for RYGBP as well as for SG or GB.

According to the data on German Nationwide Survey in BOLD-Registry there was no influence of operation on the incidence of VTE. BOLD Registry shows an incidence of VTE after GB of 0.16% and after BPD of 5.56%. Risk for VTE was higher if operation was performed at laparoscopic approach (1.53% versus 0.34%) \[[@B15]\].

In German Nationwide Survey in patients with BMI of 45 kg/m² to 49.9 kg/m² the highest risk of VTE and PE was observed. Patients developing PE were in average 4.9 years older, had on average an 3.9 kg/m² higher BMI, and had a higher incidence of VTE in medical history 16.5% versus 3.7%. The gender-specific aspect of VTE and PE was not detected in German Nationwide Survey. Data of Winegar et al. show a higher risk for male patient (HR 2.32, 95% CI 1.81--2.98) \[[@B15]\].The problem of BOLD Registry is missing informations on medication, dose of medication, and peri- and postoperative treatment.

Scholten et al. have shown the positive effect of a certain dosage of Enoxaparin on the risk for PE. Higher doses resulted in a significantly lower rate of PE. A higher incidence of bleeding was not estimated \[[@B19]\]. Data contrary to the association of dosage and BMI have been obtained in a randomized study by Kalfarentzos et al., who did not observe any difference in the frequency of thromboembolic episodes under various dosages of Fraxiparin \[[@B20]\]. Data of German Nationwide Survey did not evaluate a higher incidence of bleeding when using a higher dosage of LWMH. At the most participating centers, a higher dosage is used only in high BMI patients without using exactly weight-adjusted LMWH. Further studies favor the administration of unfractionated-heparin depending on the monitoring of factors Xa in high-risk patients \[[@B21]--[@B23]\]. However, the associations between the anti-Factor-Xa level, dosage of LWMH, and occurrence of bleeding have been excluded in a previous study \[[@B24]\].

Evidence-based data on the optimal duration; type and dosage of LWMH for prophylaxis of VTE and PE do not exist in the literature.

Cohort analysis of 17, 434 patients after bariatric operations describe an outpatient department VTE incidence of 0.88%. More than 74% of thromboembolic complications occur after patients discharge and one-third after 1 month postoperatively. Highest incidence of VTE and PE was observed after RYGBP (OR = 0.31). Evaluated risk factors are male gender (OR = 1.68), age above 55 years (OR = 2.18), nicotine abuse (OR = 1.86), and medical history of VTE (OR = 7.48) \[[@B25]\]. Data of "PROBE-Study" had evaluated as risk factors for the development of a PE after bariatric surgery, smoking, age \>40 years, BMI \>60 kg/m², and previous history of venous thromboembolism \[[@B11]\].

For high-risk patients with a BMI \>50 kg/m², a medical history of VTE, surgical interventions at the pelvis, and heart failure in further studies, the positive effect of an IVC filter was found \[[@B26]--[@B29]\].

Actual data on PE and VTE in bariatric surgery show similar to evaluated data of German Nationwide Survey on bariatric surgery a low incidence of 0.49% (*n* = 29, 323) \[[@B9], [@B15], [@B30]\]. The current ASMBS statement recommends performing compression therapy and medication for the prophylaxis of thromboembolism. The AWMF guidelines classify patients with a BMI \>30 kg/m² as high risk, but there is a lack of appropriate recommendations for the prophylaxis of thromboembolism in bariatric surgery \[[@B6], [@B9]\].

5. Conclusions and Recommendations {#sec5}
==================================

Present published review on thromboembolism after laparoscopic bariatric surgery has shown that available evidence on use of antithrombotic prophylaxis is limited \[[@B9]\].

Based on a literature search, the following predictive factors were evaluated for the occurrence of thromboembolism after bariatric interventions: age above 50 years,smoking,thrombosis/pulmonary embolism in medical history \[[@B31], [@B32]\],venous stasis \[[@B16]\],BMI \> 50 kg/m²,visceral obesity,pulmonary hypoventilation \[[@B13]\],ventricle septum defect (VSD) and aortic stenosis \[[@B33]\].

The dosage of NMH should be adapted for risk patients with BMI \> 50 kg/m² \[[@B34]\], age above 50 years, male gender, venous insufficiency, hypoventilation syndrome, smoking, and thrombosis in the medical history.

However, evidence-based data on the recommendations mentioned above are lacking. Therefore, randomized or observational studies with large number of cases are required to optimize medication and mechanical and interventional prophylaxis for thromboembolism \[[@B9], [@B16], [@B35], [@B36]\].
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BIB:

:   Intragastric balloon

BPD:

:   Biliopancreatic diversion

GB:

:   Gastric banding

DS:

:   Duodenal switch

NMH:

:   Heparin of low molecular weight

PE:

:   Pulmonary embolism

RYGBP:

:   Roux-en-Y gastric bypass

SG:

:   Sleeve gastrectomy

VTE:

:   Deep venous thrombosis.

###### 

Incidence of comorbidities.

                                  Total   
  ------------------------------- ------- ------
  Hypertension                    7042    57.3
  Skeleton disease                5366    43.6
  Sleep apnoea                    2380    19.4
  Noninsulin dependent diabetes   2347    19.1
  Pulmonary disease               2153    17.5
  Without                         2001    16.3
  GERD                            1836    14.9
  Cardiac disease                 1193    9.7
  Nicotin abuse                   275     2.2
  LE in medical history           108     0.9

###### 

VTE prophylaxis in dependence on operation.

  Year    2005 (%)   2006 (%)   2007 (%)   2008 (%)   2009 (%)   2010 (%)   Total (%)
  ------- ---------- ---------- ---------- ---------- ---------- ---------- -----------
  BIB     54.2       59.5       23.6       21.9       28.6       32.7       36.7
  GB      100        99.2       96.9       98.5       97.7       95.6       97.9
  SG                            97.7       99.2       96.1       99.4       98.8
  RYGBP   100        100        99.3       99.8       97.0       99.2       99.2
  BPD     100        100        100        100        100        100        100
  DS      100        100        100        100        100        100        100

###### 

Duration on VTE prophylaxis in days.

  Year                                     2005           2006           2007           2008            2009            2010
  ---------------------------------------- -------------- -------------- -------------- --------------- --------------- ---------------
  Mean length of prophylaxis in days (d)   6.86 (1--47)   7.62 (1--52)   7.16 (1--86)   8.20 (1--210)   9.07 (1--110)   9.15 (1--105)
  Median of prophylaxis in days (d)        7              7              6              6               6               6

###### 

Correlation between BMI and VTE prophylaxis.

  BMI (kg/m^²^)                                      Year                          
  ---------------------- ------- --------- --------- --------- --------- --------- ---------
  Applications per day                                                             
   Once daily            48.5    48.3      48.1      48.4      48.4      48.4      48.4
   Twice daily           50.0    55.0      51.5      51.6      51.0      51.6      51.5
    *P*                  0.179   \<0.001   \<0.001   \<0.001   \<0.001   \<0.001   \<0.001

###### 

Diagnosed events of VTE and PE during the first 90 postoperative days in dependence on operative procedure.

  -------------------------------------------------------------------------------------------------------------------------------------------------------
  Procedure   Number of patients (*n*)   Number of VTE (*n*)   VTE risk\                       Number of patients (*n*)   PE risk\
                                                               (95% confidence interval) (%)                              (95% confidence interval) (%)
  ----------- -------------------------- --------------------- ------------------------------- -------------------------- -------------------------------
  SG          3026                       3                     0.10 (0.02--0.29)               6                          0.20 (0.07--0.43)

  RYGBP       4901                       3                     0.06 (0.01--0.18)               3                          0.06 (0.01--0.18)

  GB          2730                       2                     0.07 (0.01--0.26)               1                          0.04 (0.00--0.20)
  -------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Diagnosed events of VTE and PE during the first 90 postoperative days in dependence on gender and BMI.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                VTE risk\                       VTE relative risk (95% confidence interval) (%)   *P*                 PE risk\                        PE relative risk (95% confidence interval) (%)   *P*
                (95% confidence interval) (%)                                                                         (95% confidence interval) (%)                                                    
  ------------- ------------------------------- ------------------------------------------------- ------------------- ------------------------------- ------------------------------------------------ --------
  Male          0.09 (0.02--0.27)               1.3691 (0.5594--3.3509)                           0.5085              0.12 (0.03--0.31)               1.3242 (0.6056--2.8953)                          0.5216

  Female        0.06 (0.02--0.14)               0.8608 (0.5032--1.4725)                           0.08 (0.03--0.17)   0.8773 (0.5611--1.3715)                                                          

                                                                                                                                                                                                       

  BMI (kg/m²)                                                                                                                                                                                          

   30.0--34.9   0.00 (---)                                                                                            0.00 (---)                                                                       

   35.0--39.9   0.00 (---)                                                                                            0.00 (---)                                                                       

   40.0--44.9   0.07 (0.01--0.26)               1.129                                             0.3090              0.04 (0.00--0.20)               0.342 (0.040--2.929)                             0.7783

   45.0--49.9   0.11 (0.02--0.32)               1.682                                                                 0.18 (0.06--0.42)               1.697 (0.491--5.866)                             

   \>50.0       0.06 (0.01--0.19)               1.000                                                                 0.11 (0.03--0.25)               1.000                                            
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

[^1]: Academic Editor: Domenico Prisco
